Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Nature Chemical Biology
|
May 19, 2011
Getting pharmaceutical R&D back on target
Mark E Bunnage
Current Opinion in Drug Discovery & Development
|
July 5, 2008
TAFIa inhibitors in the treatment of thrombosis
Mark E Bunnage, Dafydd R Owen
Nature Reviews. Drug Discovery
|
January 21, 2017
Applications of chemogenomic library screening in drug discovery
Lyn H Jones, Mark E Bunnage
Nature Chemical Biology
|
March 20, 2013
Target validation using chemical probes
Mark E Bunnage, Eugene L Piatnitski Chekler, Lyn H Jones
Nature Chemical Biology
|
May 17, 2015
Know your target, know your molecule
Mark E Bunnage, Adam M Gilbert, Lyn H Jones, et al.
Organic Letters
|
January 31, 2003
Asymmetric synthesis of the putative structure of (-)-oryzoxymycin
Mark E Bunnage, Thota Ganesh, Ishmael B Masesane, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 28, 2008
Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule
Mark E Bunnage, John P Mathias, Anthony Wood, et al.
Organic & Biomolecular Chemistry
|
September 30, 2004
Asymmetric synthesis of the cis- and trans-stereoisomers of 4-aminopyrrolidine-3-carboxylic acid and 4-aminotetrahydrofuran-3-carboxylic acid
Mark E Bunnage, Stephen G Davies, Paul M Roberts, et al.
Organic & Biomolecular Chemistry
|
December 3, 2003
Asymmetric synthesis of (1R,2S,3R)-3-methylcispentacin and (1S,2S,3R)-3-methyltranspentacin by kinetic resolution of tert-butyl (+/-)-3-methylcyclopentene-1-carboxylate
Mark E Bunnage, Ann M Chippindale, Stephen G Davies, et al.
Organic & Biomolecular Chemistry
|
November 10, 2004
Kinetic resolution of tert-butyl (RS)-3-alkylcyclopentene-1-carboxylates for the synthesis of homochiral 3-alkyl-cispentacin and 3-alkyl-transpentacin derivatives
Mark E Bunnage, Stephen G Davies, Richard M Parkin, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Nature Chemical Biology
|
May 19, 2011
Getting pharmaceutical R&D back on target
Mark E Bunnage
Current Opinion in Drug Discovery & Development
|
July 5, 2008
TAFIa inhibitors in the treatment of thrombosis
Mark E Bunnage, Dafydd R Owen
Nature Reviews. Drug Discovery
|
January 21, 2017
Applications of chemogenomic library screening in drug discovery
Lyn H Jones, Mark E Bunnage
Nature Chemical Biology
|
March 20, 2013
Target validation using chemical probes
Mark E Bunnage, Eugene L Piatnitski Chekler, Lyn H Jones
Nature Chemical Biology
|
May 17, 2015
Know your target, know your molecule
Mark E Bunnage, Adam M Gilbert, Lyn H Jones, et al.
Organic Letters
|
January 31, 2003
Asymmetric synthesis of the putative structure of (-)-oryzoxymycin
Mark E Bunnage, Thota Ganesh, Ishmael B Masesane, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 28, 2008
Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule
Mark E Bunnage, John P Mathias, Anthony Wood, et al.
Organic & Biomolecular Chemistry
|
September 30, 2004
Asymmetric synthesis of the cis- and trans-stereoisomers of 4-aminopyrrolidine-3-carboxylic acid and 4-aminotetrahydrofuran-3-carboxylic acid
Mark E Bunnage, Stephen G Davies, Paul M Roberts, et al.
Organic & Biomolecular Chemistry
|
December 3, 2003
Asymmetric synthesis of (1R,2S,3R)-3-methylcispentacin and (1S,2S,3R)-3-methyltranspentacin by kinetic resolution of tert-butyl (+/-)-3-methylcyclopentene-1-carboxylate
Mark E Bunnage, Ann M Chippindale, Stephen G Davies, et al.
Organic & Biomolecular Chemistry
|
November 10, 2004
Kinetic resolution of tert-butyl (RS)-3-alkylcyclopentene-1-carboxylates for the synthesis of homochiral 3-alkyl-cispentacin and 3-alkyl-transpentacin derivatives
Mark E Bunnage, Stephen G Davies, Richard M Parkin, et al.
Page
of 4